{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:13Z","timestamp":1793105053650,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1179906"],"award-info":[{"award-number":["OPP1179906"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1159947"],"award-info":[{"award-number":["OPP1159947"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV001759"],"award-info":[{"award-number":["INV001759"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV010271"],"award-info":[{"award-number":["INV010271"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1159947"],"award-info":[{"award-number":["OPP1159947"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of an effective and durable vaccine remains a central goal in the fight against malaria. Circumsporozoite protein (CSP) is the major surface protein of sporozoites and the target of the only licensed <jats:italic>Plasmodium falciparum<\/jats:italic> (Pf) malaria vaccine, RTS,S\/AS01. However, vaccine efficacy is low and short-lived, highlighting the need for a second-generation vaccine with superior efficacy and durability. Here, we report a <jats:italic>Helicobacter pylori<\/jats:italic> apoferritin-based nanoparticle immunogen that elicits strong B cell responses against PfCSP epitopes that are targeted by the most potent human monoclonal antibodies. Glycan engineering of the scaffold and fusion of an exogenous T cell epitope enhanced the anti-PfCSP B cell response eliciting strong, long-lived and protective humoral immunity in mice. Our study highlights the power of rational vaccine design to generate a highly efficacious second-generation anti-infective malaria vaccine candidate and provides the basis for its further development.<\/jats:p>","DOI":"10.1038\/s41541-023-00653-7","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T05:02:37Z","timestamp":1680843757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2624-8180","authenticated-orcid":false,"given":"Julia","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-7772","authenticated-orcid":false,"given":"Stephen W.","family":"Scally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-1735","authenticated-orcid":false,"given":"Sandro","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-7268","authenticated-orcid":false,"given":"Rajagopal","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Lossin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-5935","authenticated-orcid":false,"given":"Katherine","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8768-3921","authenticated-orcid":false,"given":"Anna","family":"Obraztsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Lobeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Franke-Fayard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-6205","authenticated-orcid":false,"given":"Chris J.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spela","family":"Binter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Levashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-5933","authenticated-orcid":false,"given":"Hedda","family":"Wardemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7602-3995","authenticated-orcid":false,"given":"Jean-Philippe","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"653_CR1","unstructured":"WHO. World Malaria Report 2021 (WHO Press, 2021)."},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0166-6851(97)00124-2","volume":"90","author":"SP Sidjanski","year":"1997","unstructured":"Sidjanski, S. P., Vanderberg, J. P. & Sinnis, P. Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum. Mol. Biochem. Parasitol. 90, 33\u201341 (1997).","journal-title":"Mol. Biochem. Parasitol."},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/385336a0","volume":"385","author":"R M\u00e9nard","year":"1997","unstructured":"M\u00e9nard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385, 336\u2013339 (1997).","journal-title":"Nature"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1371\/journal.pbio.0030192","volume":"3","author":"U Frevert","year":"2005","unstructured":"Frevert, U. et al. Intravital observation of plasmodium berghei sporozoite infection of the liver. PLoS Biol. 3, e192 (2005).","journal-title":"PLoS Biol."},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/0092-8674(92)90251-7","volume":"70","author":"C Cerami","year":"1992","unstructured":"Cerami, C. et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites. Cell 70, 1021\u20131033 (1992).","journal-title":"Cell"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.6204384","volume":"225","author":"V Enea","year":"1984","unstructured":"Enea, V. et al. DNA cloning of plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 225, 628\u2013630 (1984).","journal-title":"Science"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite plasmodium falciparum. Science 225, 587\u2013593 (1984).","journal-title":"Science"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.vaccine.2010.05.033","volume":"28","author":"S Casares","year":"2010","unstructured":"Casares, S., Brumeanu, T. D. & Richie, T. L. The RTS,S malaria vaccine. Vaccine 28, 4880\u20134894 (2010).","journal-title":"Vaccine"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","volume":"336","author":"JA Stoute","year":"1997","unstructured":"Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. N. Engl. J. Med. 336, 86\u201391 (1997).","journal-title":"N. Engl. J. Med."},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","volume":"19","author":"J-P Julien","year":"2019","unstructured":"Julien, J.-P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19, 761\u2013775 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.1205737109","volume":"109","author":"MB Doud","year":"2012","unstructured":"Doud, M. B. et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl Acad. Sci. USA. 109, 7817\u20137822 (2012).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"e101783","DOI":"10.1371\/journal.pone.0101783","volume":"9","author":"K Gandhi","year":"2014","unstructured":"Gandhi, K. et al. Variation in the circumsporozoite protein of plasmodium falciparum: vaccine development implications. PLoS ONE 9, e101783 (2014).","journal-title":"PLoS ONE"},{"key":"653_CR13","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.1126\/sciimmunol.abm9644","volume":"7","author":"I Wahl","year":"2022","unstructured":"Wahl, I. et al. Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP. Sci. Immunol. 7, 9644 (2022).","journal-title":"Sci. Immunol."},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1002\/j.1460-2075.1988.tb03104.x","volume":"7","author":"M Guttinger","year":"1988","unstructured":"Guttinger, M. et al. Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein. EMBO J. 7, 2555\u20132558 (1988).","journal-title":"EMBO J."},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1073\/pnas.85.4.1199","volume":"85","author":"MF Good","year":"1988","unstructured":"Good, M. F. et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl Acad. Sci. USA 85, 1199\u20131203 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4049\/jimmunol.151.1.489","volume":"151","author":"A Moreno","year":"1993","unstructured":"Moreno, A. et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151, 489\u2013499 (1993).","journal-title":"J. Immunol."},{"key":"653_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-120","volume":"8","author":"A Jalloh","year":"2009","unstructured":"Jalloh, A., Jalloh, M. & Matsuoka, H. T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: Age-dependent haplotype distribution? Malar. J. 8, 120 (2009).","journal-title":"Malar. J."},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. N. Engl. J. Med 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med"},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"SCTP RTS","year":"2015","unstructured":"RTS, S. C. T. P. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"653_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03961-2","volume":"20","author":"RM Mugo","year":"2021","unstructured":"Mugo, R. M. et al. Seven-year kinetics of RTS, S\/AS01-induced anti-CSP antibodies in young Kenyan children. Malar. J. 20, 452 (2021).","journal-title":"Malar. J."},{"key":"653_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo, M. S. et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728\u20131736 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"653_CR23","first-page":"1","volume":"1","author":"A Birkett","year":"2022","unstructured":"Birkett, A., Miller, R. S. & Soisson, L. A. The importance of exercising caution when comparing results from malaria vaccines administered on the EPI schedule and on a seasonal schedule. Am. J. Trop. Med. Hyg. 1, 1 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1126\/sciimmunol.aap8029","volume":"3","author":"R Murugan","year":"2018","unstructured":"Murugan, R. et al. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Sci. Immunol. 3, 8029 (2018).","journal-title":"Sci. Immunol."},{"key":"653_CR25","doi-asserted-by":"publisher","first-page":"e20200061","DOI":"10.1084\/jem.20200061","volume":"217","author":"E Thai","year":"2020","unstructured":"Thai, E. et al. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity. J. Exp. Med. 217, e20200061 (2020).","journal-title":"J. Exp. Med."},{"key":"653_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135\u20131145 (2020).","journal-title":"Nat. Med."},{"key":"653_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197\u20131209 e10. (2017).","journal-title":"Immunity"},{"key":"653_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744.e8. (2020).","journal-title":"Immunity"},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2018","unstructured":"Scally, S. W. et al. Rare human antibodies against the circumsporozoite protein C-terminal domain are ineffective against Pf sporozoites. J. Exp. Med. 215, 63\u201375 (2018).","journal-title":"J. Exp. Med."},{"key":"653_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"653_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"e1010409","DOI":"10.1371\/journal.ppat.1010409","volume":"18","author":"N Beutler","year":"2022","unstructured":"Beutler, N. et al. A novel CSP C-Terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. PLoS Pathog. 18, e1010409 (2022).","journal-title":"PLoS Pathog."},{"key":"653_CR33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","volume":"212","author":"DA Espinosa","year":"2015","unstructured":"Espinosa, D. A. et al. Proteolytic cleavage of the Plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111\u20131119 (2015).","journal-title":"J. Infect. Dis."},{"key":"653_CR34","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.celrep.2021.108996","volume":"35","author":"D Chatterjee","year":"2021","unstructured":"Chatterjee, D. et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Cell Rep. 35, 108996 (2021).","journal-title":"Cell Rep."},{"key":"653_CR35","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1016\/j.vaccine.2007.07.026","volume":"25","author":"MG Chaitra","year":"2007","unstructured":"Chaitra, M. G., Nayak, R. & Shaila, M. S. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine 25, 7168\u20137176 (2007).","journal-title":"Vaccine"},{"key":"653_CR36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1084\/jem.157.6.1947","volume":"157","author":"F Zavala","year":"1983","unstructured":"Zavala, F., Cochrane, A. H., Nardin, E. H., Nussenzweig, R. S. & Nussenzweig, V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J. Exp. Med. 157, 1947\u20131957 (1983).","journal-title":"J. Exp. Med."},{"key":"653_CR37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228, 1436\u20131440 (1985).","journal-title":"Science"},{"key":"653_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00430-y","volume":"7","author":"MD Langowski","year":"2022","unstructured":"Langowski, M. D. et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. npj Vaccines 7, 1\u201311 (2022).","journal-title":"npj Vaccines"},{"key":"653_CR39","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1073\/pnas.1911792117","volume":"117","author":"MD Langowski","year":"2020","unstructured":"Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl Acad. Sci. USA 117, 3114\u20133122 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"653_CR40","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"653_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02788751","volume":"18","author":"J Alexander","year":"1998","unstructured":"Alexander, J. et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Res. 18, 79\u201392 (1998).","journal-title":"Immunologic Res."},{"key":"653_CR42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nbt.2825","volume":"32","author":"E-C Lee","year":"2014","unstructured":"Lee, E.-C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356\u2013363 (2014).","journal-title":"Nat. Biotechnol."},{"key":"653_CR43","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358\u20131362 (2018).","journal-title":"Science"},{"key":"653_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383\u2013391 (2022).","journal-title":"Nat. Med."},{"key":"653_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"653_CR46","doi-asserted-by":"crossref","unstructured":"Rivera-Hernandez, T. et al. Vaccine-induced th1-type response protects against invasive group a Streptococcus infection in the absence of opsonizing antibodies. MBio 11 (2020).","DOI":"10.1128\/mBio.00122-20"},{"key":"653_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20151960","volume":"213","author":"R Rappuoli","year":"2016","unstructured":"Rappuoli, R., Bottomley, M. J., D\u2019Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469\u2013481 (2016).","journal-title":"J. Exp. Med."},{"key":"653_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10262-5","volume":"10","author":"K Sliepen","year":"2019","unstructured":"Sliepen, K. et al. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nat. Commun. 10, 1\u201316 (2019).","journal-title":"Nat. Commun."},{"key":"653_CR49","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"653_CR50","doi-asserted-by":"publisher","first-page":"6466","DOI":"10.1126\/sciimmunol.aba6466","volume":"5","author":"KA Swanson","year":"2020","unstructured":"Swanson, K. A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. 5, 6466 (2020).","journal-title":"Sci. Immunol."},{"key":"653_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1074-7613(94)80017-0","volume":"1","author":"J Alexander","year":"1994","unstructured":"Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751\u2013761 (1994).","journal-title":"Immunity"},{"key":"653_CR52","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1016\/j.vaccine.2014.02.024","volume":"32","author":"CC Fraser","year":"2014","unstructured":"Fraser, C. C. et al. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine 32, 2896\u20132903 (2014).","journal-title":"Vaccine"},{"key":"653_CR53","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.xcrm.2022.100780","volume":"3","author":"JC Kraft","year":"2022","unstructured":"Kraft, J. C. et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell Rep. Med. 3, 100780 (2022).","journal-title":"Cell Rep. Med."},{"key":"653_CR54","doi-asserted-by":"publisher","first-page":"110217","DOI":"10.1016\/j.celrep.2021.110217","volume":"38","author":"BJ Read","year":"2022","unstructured":"Read, B. J. et al. Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens. Cell Rep. 38, 110217 (2022).","journal-title":"Cell Rep."},{"key":"653_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.aat9120","volume":"363","author":"T Tokatlian","year":"2019","unstructured":"Tokatlian, T. et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science 363, 649\u2013654 (2019).","journal-title":"Science"},{"key":"653_CR56","doi-asserted-by":"publisher","first-page":"e1001112","DOI":"10.1371\/journal.ppat.1001112","volume":"6","author":"C Harris","year":"2010","unstructured":"Harris, C. et al. Polymorphisms in Anopheles gambiae Immune Genes Associated with Natural Resistance to Plasmodium falciparum. PLoS Pathog. 6, e1001112 (2010).","journal-title":"PLoS Pathog."},{"key":"653_CR57","doi-asserted-by":"publisher","first-page":"e1002255","DOI":"10.1371\/journal.pbio.1002255","volume":"13","author":"J Pompon","year":"2015","unstructured":"Pompon, J. & Levashina, E. A. A new role of the mosquito complement-like cascade in male fertility in Anopheles gambiae. PLOS Biol. 13, e1002255 (2015).","journal-title":"PLOS Biol."},{"key":"653_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4269\/ajtmh.2006.74.708","volume":"74","author":"J Sattabongkot","year":"2006","unstructured":"Sattabongkot, J. et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74, 708\u2013715 (2006).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"653_CR59","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1080\/15548627.2015.1067361","volume":"11","author":"M Prado","year":"2015","unstructured":"Prado, M. et al. Long-term live imaging reveals cytosolic immune responses of host hepatocytes against plasmodium infection and parasite escape mechanisms. Autophagy 11, 1561\u20131579 (2015).","journal-title":"Autophagy"},{"key":"653_CR60","doi-asserted-by":"publisher","first-page":"e29289","DOI":"10.1371\/journal.pone.0029289","volume":"6","author":"J Lin","year":"2011","unstructured":"Lin, J. et al. A novel \u2018gene insertion\/marker out\u2019 (GIMO) method for transgene expression and gene complementation in rodent malaria parasites. PLoS One 6, e29289 (2011).","journal-title":"PLoS One"},{"key":"653_CR61","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nprot.2006.53","volume":"1","author":"CJ Janse","year":"2006","unstructured":"Janse, C. J., Ramesar, J. & Waters, A. P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat. Protoc. 1, 346\u2013356 (2006).","journal-title":"Nat. Protoc."},{"key":"653_CR62","unstructured":"Salman, A. M. et al. In Methods in Molecular Biology 1325, 257-286 (Humana Press Inc., 2015)."},{"key":"653_CR63","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 11 (R Core Team). https:\/\/www.r-project.org."}],"updated-by":[{"DOI":"10.1038\/s41541-023-00687-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00653-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:58:49Z","timestamp":1686070729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00653-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00653-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41541-023-00687-x","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"25 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41541-023-00687-x","URL":"https:\/\/doi.org\/10.1038\/s41541-023-00687-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H., J. Lossin, A.O., N.L., B.F., C.J.J., S. B., P.K. declare no conflicts of interest. J. Ludwig, S.W.S., G.C., R.M., K.P., H.W., E.A.L. and J.-P.J. have filed a patent application related to the immunogens described in this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}